

**PATENT** 

Attorney Docket No.: 28594/38247

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shannon et al.	) I hereby certify that this paper is being
Serial No.: 10/049,953	<ul><li>deposited with the United States Postal</li><li>Service as first class mail, postage</li></ul>
Filed: February 19, 2002	<ul><li>) prepaid, in an envelope addressed to:</li><li>) Commissioner for Patents, Box PCT,</li></ul>
1 100. 1 coldaly 19, 2002	) Washington, DC 20231 on this date:
For: Recombinant Subunit Vaccine	)
Crown Aut Huite To Leave 1	)
Group Art Unit: To be assigned	) April 2, 2002
Examiner: To be assigned	Brank-Call
	Thomas A. Caurley, Jr. DI. D.
	) Thomas A. Cawley, Jr., Ph.D. ) Registration No. 40,994
	,
	) Attorney for Applicants

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Commissioner for Patents Box PCT Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the applicants call to the attention of the examiner the enclosed publications, as listed on the attached Form PTO-1449, which may be considered material to the examination of the above-identified patent application.

Documents B1-B6 and C2-C3 were cited in the international search report of counterpart international patent appl. no. PCT/AU00/00988 (document C1 on the enclosed PTO-1449).

This information disclosure statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This information disclosure statement is submitted before receipt of a first official action on the merits and consequently should be considered by the Patent Office without payment of a fee [see 37 C.F.R. §1.97(b)]. However, should the Patent Office determine that a fee is due for consideration of this information disclosure statement and accompanying publications, the Patent Office is hereby authorized to charge said fee to Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606-6402 (312) 474-6300

By:

Thomas A. Cawley, Jr., Ph.D.

Reg. No.: 40,994

April 2, 2002

U.S. Department of Commerce Patent and Trademark Office

Atty. Docke 28594/38247

Serial No. 10/049,953

Applicant

Shannon et al.

Filing Date February 19, 2002 Group **TBA** 

(Use several sheets if necessary)

		U.S. PATE	NT DOCUMENT	S		
*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS								
*Examiner	Document Publication Country Class	CI		Translation				
Initials		Number	Date	Country	Class	Subclass	Yes	No
•  -	B1	WO 98/23735	6/4/98	WO				
	B2	WO 99/07860	2/18/99	WO				
	В3	WO 99/29384	6/17/99	wo				
	B4	WO 99/42121	8/26/99	wo				
	B5	WO 99/42472	8/26/99	WO				
	В6	WO 00/20606	4/13/00	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
	C1	International Search Report, International Application No. PCT/AU00/00988, International Filing Date 18 August 2000, Applicant Minister for Agriculture, Minister for Land and Water Conservation for and on Behalf of the State of Newsouth Wales et al.			
	C2	Rico et al., "Characterization of the immunostimulatory properties of Leishmania infanttum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice," <i>Infection and Immunity</i> , 66(1):347-352 (1998).			
	C3	Schirmbeck et al., "Truncated of chimeric endogenous protein antigens gain immunogeniteity for B cells by stress protein-facilitated expression," <i>European J. Immunol.</i> , 29(5): (1999).			

EXA	MIN	ER

DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.